Short-term and long-term open evaluation of the efficacy and tolerance of proglumetacin, a new antirheumatic agent
Thirty-three patients were treated with proglumetacin for acute joint inflammation (11 cases, 450 mg daily for 3 weeks) or chronic rheumatic disorders (22 patients, 300 mg daily for 12 weeks). The results showed that swelling had completely disappeared during the first week and joint pain by the thi...
| Publié dans: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 3(1982), 3 vom: 31., Seite 174-9 |
|---|---|
| Auteur principal: | |
| Format: | Article |
| Langue: | English |
| Publié: |
1982
|
| Accès à la collection: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC) |
| Sujets: | Journal Article Anti-Inflammatory Agents Indoleacetic Acids proglumetacin FV919079LU |